Latest news with #FamilialAdenomatousPolyposis
Yahoo
23-06-2025
- Business
- Yahoo
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ('Biodexa' or 'the Company'), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (FAP). In conjunction with this announcement, the company launched a dedicated website, to provide information and resources for patients, caregivers, and healthcare professionals. Serenta reflects Biodexa's commitment to supporting the FAP community and fostering collaboration with stakeholders. The new website offers details about the study's objectives, background on FAP, and ongoing updates as the program progresses. 'We are pleased to introduce Serenta as the identity for our planned pivotal study of eRapa in FAP,' said Gary Shangold, CMO at Biodexa. 'Our goal is to provide clear, accessible information and to engage with the FAP community as we advance this important work.' For more information, please visit About eRapa eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis3. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 20480 180 About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
Yahoo
24-05-2025
- Business
- Yahoo
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Increased Net Loss Despite Rising Sales
Recursion Pharmaceuticals reported a 10% decline in its share price last week as it announced first-quarter 2025 results with an increased net loss despite rising sales and revenue. However, the company's clinical progress, highlighted by preliminary results from its REC-4881 trial for Familial Adenomatous Polyposis, may have provided some counterbalance to this decline. While its price movement aligns with a broader market drop of 3%, the market has seen gains over the past year, suggesting Recursion's financial challenges may have weighed more heavily on short-term investor sentiment. We've spotted 3 possible red flags for Recursion Pharmaceuticals you should be aware of, and 1 of them is a bit concerning. We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent decline in Recursion Pharmaceuticals' share price following the announcement of increased net loss despite rising sales and revenue underscores the company's current financial challenges. Over a longer period, the company's total return was a 33.87% decline over the past three years, reflecting ongoing struggles to balance cash flow against high R&D expenses and clinical uncertainties. Compared to broader market trends, Recursion has also underperformed, trailing both the US Market's 9% gain and the US Biotechs industry's 13.2% decline over the past year, highlighting investor concerns over profitability and financial stability. The news of clinical progress in trials like REC-4881 does provide a glimmer of optimism for future revenue growth as these advancements might lead to marketable products. However, revenue and earnings forecasts remain clouded by high cash burn and reliance on unpredictable milestone payments, indicating potential volatility. The company's current US$5.72 share price trades at a discount to the consensus price target of US$8.71, suggesting that analysts see potential upside if Recursion can overcome its financial hurdles and realize expected efficiencies and computational advances. This gap highlights the market's cautious stance, driven by uncertainty over achieving the projected growth targets. Understand Recursion Pharmaceuticals' earnings outlook by examining our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:RXRX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-03-2025
- Health
- Yahoo
Spaghetti dinner fundraises for Boardman senior with rare genetic condition
BOARDMAN, Ohio (WKBN) — Dozens of people filled the Boardman High School on Sunday in support of one senior. Kayden Beish has Familial Adenomatous Polyposis, a rare genetic mutation that doesn't protect against the growth of polyps. She has 100 polyps in her GI tract right now. Sunday was her Kayden's Krew spaghetti dinner. 'It's just really heartwarming, like it's so warming to see everyone come out to support me and my family with what's going on,' Beish said. Beish's next testing at the hospital will be in June. For now, she's looking forward to graduating and attending college. Tino DiCenso contributed to this report. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
21-03-2025
- Health
- Yahoo
Boardman High School senior diagnosed with rare condition
BOARDMAN, Ohio (WKBN) — A Boardman High School senior recently diagnosed with a rare condition is up for the fight after receiving the devasting news. Kayden Beish has FAP, Familial Adenomatous Polyposis, a genetic mutation in genes that would normally protect against the growth of polyps. 'It's really hard to even think about at my age, especially,' Beish said. Beish is 18. She's had stomach pain for years but was just diagnosed with FAP last year. She has 100 polyps right now in her GI tract. 'I have good days and bad days, so sometimes I'll have a lot of pain and I can't go to school, I can't go to work or hang out with my friends,' she said. FAP usually leads to colon cancer. It's not pretty to think about but her Mom believes in her. 'If anybody can handle this, it is Kayden. She perseveres and pushes through and overcomes anything that's thrown at her,' said her mother Katie Fuline. FAP was a giant diagnosis, words the family had never heard. It's even tougher for a girl during her senior year, looking forward to life. Beish will have to think about surgeries and whether it could lead to something worse. 'And that's our goal, is to just keep up with the testing and keep on top of it, and never let this get to cancer. But you never know,' Fuline said. Beish is going to Hawaii over spring break. The trip is from Make A Wish. 'Kayden's Krew' bracelets also show the support she's getting from her family and at school to keep her spirits up. And later this month, a spaghetti dinner will raise vital support to help her now and in the future — because there's no cure for FAP. 'I never want there to be a time where she says I can't get testing done, or I can't have a surgery done because I don't have the money available for it,' Fuline said. FAP is something Kayden will keep fighting. Kayden's Krew Spaghetti Dinner will be March 30 at the Boardman High School cafeteria from 1-5 p.m. Tickets for those 13 and up cost $12, children 5-12 are $8 and kids under four are free. In addition, there will be basket raffles and a bake sale. You can even donate cookies or cakes to be sold. To purchase tickets or donate baskets call Marlene at 330-207-6304 or Heidi at 330-984-5735. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
